# METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D)

> **NCT07699380** · PHASE2 · RECRUITING · sponsor: **University of Washington** · enrollment: 60 (estimated)

## Conditions studied

- Type 1 Diabetes (T1D)
- Metabolic Diseases
- Glucose Metabolism Disorders
- Endocrine System Diseases
- Autoimmune Diseases
- Immune System Diseases
- Diabetes Melletus, Type 1
- Nutritional and Metabolic Diseases
- Combination Therapy

## Interventions

- **DRUG:** AMX0035
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07699380
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2029-12
- **Final completion:** 2029-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-09-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07699380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07699380, "METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07699380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*